In their neo-adjuvant clinical trial, the researchers also found that the levels of the immunosuppressive cytokine were significantly higher in ExVs isolated from the serum of HER2-overexpressing BC patients who did not respond to HER2-targeted drug treatment than those who experienced complete or partial response. Here, ERBB2 is linked to breast cancer.